about
Site-Specific PEGylation of Therapeutic ProteinsAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialCheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral ReservoirsIntra-articular transplantation of atsttrin-transduced mesenchymal stem cells ameliorate osteoarthritis development.Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1-Type Response.TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry studyDrug delivery technologies for autoimmune disease.Immunoconjugates and long circulating systems: origins, current state of the art and future directionsTreatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors.Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists.Biological therapy for ulcerative colitis.Certolizumab pegol for the treatment of psoriatic arthritis.Trojan horses and guided missiles: targeted therapies in the war on arthritis.Recent advances in nanomedicines for the treatment of rheumatoid arthritis.Targeting collagen for diagnostic imaging and therapeutic delivery.Chemical Protein Modification through Cysteine.Towards the next generation of biomedicines by site-selective conjugation.Cytokine binding by polysaccharide-antibody conjugates.Evading pre-existing anti-hinge antibody binding by hinge engineering.Comparative Study of In Situ Loaded Antibody and PEG-Fab NIPAAM Gels.Tocilizumab (Actemra).Irreversible Cysteine-Selective Protein Labeling Employing Modular Electrophilic Tetrafluoroethylation Reagents.Development of a generic β-lactamase screening system for improved signal peptides for periplasmic targeting of recombinant proteins in Escherichia coli.Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis.Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy.Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis
P2860
Q26777819-5C4E2AE1-C016-444E-8DA8-A5B454EAD9BCQ26829488-13A3ACDA-CF97-43A2-AEC0-17AF4C1D4A7AQ33584492-0D52C60D-B449-4712-9CC7-E97B847C25E5Q33613493-0533ECFB-80CF-49D6-9A8F-7F57889D8D79Q35552093-03F304B4-3912-47BE-BF08-26E45E616123Q35758262-8159B8F9-7AE4-4B2A-A805-E0470D4685C2Q37283495-2A6EC67B-F67F-43E8-9A7A-FA7AB665E4D8Q37433321-E1A838A7-A567-4957-B7CB-5F91C0C19A49Q37494175-170D0E81-CAA2-4EBF-A0E2-F1738C421CE0Q37801381-61F20165-D119-48F7-AE0F-FAC87A1E7584Q38042256-65F4EAE5-5F70-4475-AA41-B43A77059D50Q38172584-CBABD3D8-3D0A-4E94-8E22-F09AF63E5840Q38200926-C8226BC8-A9BC-40A7-ACCD-5CD5796B7207Q38239111-5E3BA35F-1284-4C03-BCE3-D9D61F2D8C1BQ38262662-7CE47BB2-EDEF-42C4-BA24-39CF626B83CFQ38344194-55F88B26-8692-4336-B1E3-F5A94D87304CQ38367194-2D8A954C-10FF-4DB0-9B2A-8796E09BE00BQ38669113-2D4F6991-2504-49CD-8741-3C15EAA1E92EQ38698660-6D40577D-EE29-4FC5-8AF4-1A2286FE7DF9Q38704033-186153CE-995D-4BB4-BE22-EA81559CFDACQ38706553-921C0857-19A4-4B46-A409-BFFA241BF3A5Q39665229-1942C2C0-729F-45C6-93B1-E272CA7AA853Q42027130-C23335CF-1695-4772-860A-516180B866F3Q47330134-29020FF1-7786-4CDD-84BF-094DE3850D67Q47978774-90F59FA0-9743-44AE-B3D5-8794F634CEBAQ48240125-A3B56926-0EBE-4177-AB9D-44E5976601C1Q53068934-98724C75-D610-495C-86E2-F9B359229F9AQ55000881-5E22CA58-6C14-4C8E-B03A-21CE9D94C713Q55073579-87055417-329D-462B-A0DF-5CBF53202BE2Q57330038-5BB1A945-705E-4E63-9ACB-8F1E5D0B3C7E
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Certolizumab pegol
@ast
Certolizumab pegol
@en
Certolizumab pegol
@nl
type
label
Certolizumab pegol
@ast
Certolizumab pegol
@en
Certolizumab pegol
@nl
prefLabel
Certolizumab pegol
@ast
Certolizumab pegol
@en
Certolizumab pegol
@nl
P2860
P3181
P356
P1476
Certolizumab pegol
@en
P2093
Sue Stephens
P2860
P304
P3181
P356
10.4161/MABS.2.2.11271
P407
P50
P577
2010-03-01T00:00:00Z